Pfizer outlined a path back to stronger top-line expansion after 2028, attributing the shift to obesity drugs still in development, recent intellectual property settlements for its heart medicine Vyndamax and a European court ruling linked to its COVID-19 vaccine. The drugmaker also reported quarterly results that exceeded Wall Street forecasts, helped by demand for its blood thinner Eliquis and revenues from medicines it has recently acquired.
Management stressed that several pipeline programs could alter Pfizer’s commercial trajectory over time, but analysts said more clinical evidence and lower program risk will be required before investor sentiment meaningfully changes. J.P. Morgan analyst Chris Schott noted that while there are promising candidates in Pfizer’s research pipeline, the market will want to see additional trial data and clearer risk reduction on those programs.
Obesity strategy and market positioning
Pfizer expects its first obesity drug stemming from the company’s $10 billion acquisition of Metsera to be a later-stage contributor to revenue, with no market entry anticipated before 2028. The company’s U.S. commercial lead highlighted Pfizer’s internal strengths in the obesity field, saying the firm has distinct capabilities to engage both consumers and patients in different ways. Chief U.S. Commercial Officer Aamir Malik added that Pfizer’s sales teams already interact with roughly 60% of the physicians who are likely to prescribe obesity therapies.
CEO Albert Bourla said the company was taken aback by the scale of international demand after reviewing Eli Lilly’s recent report on its GLP-1 obesity and diabetes products. Pfizer plans to pursue growth in emerging markets such as Brazil and Mexico, where it maintains a substantial primary-care presence.
Drivers in the first quarter
Pfizer’s first-quarter performance received a lift from recently launched and acquired medicines, including cancer drug Padcev and the migraine therapy Nurtec ODT. Citi analyst Geoff Meacham pointed to 22% growth in newly launched and acquired products as evidence that Pfizer’s commercial portfolio can counterbalance continued declines in its COVID franchise.
Total first-quarter revenue reached $14.45 billion, topping analyst estimates of $13.79 billion. The company reported adjusted earnings of $0.75 per share, beating consensus by $0.03. Despite the modest beat, Pfizer maintained its full-year revenue outlook of $59.5 billion to $62.5 billion and its adjusted profit guidance of $2.80 to $3.00 per share.
Equity reaction was muted, with shares trading down by less than 1% after the results. RBC Capital analyst Trung Huynh characterized the quarter as a credibility-building moment that might support the stock in the near term but cautioned that Pfizer remains primarily a catalyst-driven story rather than one propelled solely by quarterly earnings.
Product-level detail
Sales of Eliquis, marketed in partnership with Bristol Myers Squibb, reached $2.17 billion in the quarter, well above the $1.76 billion analysts had expected. Vyndamax produced $1.6 billion in first-quarter revenue, slightly under forecasts. The company’s COVID vaccine Comirnaty generated $232 million in revenue, a 59% decline from the prior year and below expectations of $434 million.
Last week Pfizer settled patent disputes with three generic drugmakers over Vyndamax, arrangements that defer the introduction of cheaper generic versions until around mid-2031. Bourla said those settlements could substantially reshape Pfizer’s growth profile after 2028 and gave the company confidence in achieving a high-single-digit compounded annual growth rate for a five-year period beginning in 2029.
Separately, a European court decision requiring Poland and Romania to accept 1.9 billion euros of COVID vaccines produced by Pfizer and its partner BioNTech was cited as another factor that should improve the company’s outlook.
Pipeline moves and near-term development
Pfizer said it will advance a next-generation pneumococcal vaccine for adults designed to protect against 35 strains of the bacteria, with clinical development expected to start this year. Management framed this as part of ongoing efforts to broaden the company’s long-term product set while managing the decline of COVID-related sales.
Analyst perspectives and market context
Analysts emphasized the importance of additional clinical readouts and risk reduction across Pfizer’s development programs before confidence in the company’s mid-decade growth prospects strengthens. J.P. Morgan’s Chris Schott said investors need to see more data and clearer risk profiles to improve sentiment. Citi’s Geoff Meacham highlighted the offsetting effect of new and acquired medicines on waning COVID revenues. RBC’s Trung Huynh underscored that, despite a beat, Pfizer’s story hinges more on future catalysts than on recurring earnings beats.
Overall, Pfizer’s quarterly beat and strategic announcements underscore the company’s efforts to navigate a transition period marked by fading COVID product sales, pending patent expirations and a push into high-growth indications such as obesity and pneumococcal prevention.